Ehlers-Danlos syndromes

What is Ehlers-Danlos syndromes?

Ehlers-Danlos syndromes (EDS) are a group of rare connective tissue disorders that affect the structure and function of collagen, a protein that provides strength and elasticity to skin, joints, blood vessels, and organs throughout the body. These conditions affect people of all ethnicities and genders, with an estimated prevalence of approximately 1 in 5,000 individuals worldwide across all subtypes. EDS encompasses 13 different subtypes, each with distinct characteristics but sharing common features of joint hypermobility, skin hyperextensibility, and tissue fragility. While some forms cause primarily joint and skin problems, others can involve life-threatening complications affecting blood vessels and internal organs.

Key statistics

Symptoms

Joint hypermobility, skin hyperextensibility, easy bruising, chronic pain, tissue fragility, delayed wound healing, vascular complications, organ prolapse, dental problems, fatigue, gastrointestinal issues.

The presentation of EDS varies significantly depending on the subtype. Hypermobile EDS (hEDS), the most common form, primarily causes joint hypermobility leading to frequent dislocations and subluxations, chronic pain, and fatigue. Patients often experience soft, stretchy skin that bruises easily and heals slowly with characteristic “papyraceous” scars.

Classical EDS (cEDS) features pronounced skin hyperextensibility, where skin can be stretched significantly beyond normal limits, along with severe bruising and poor wound healing. Joint hypermobility is present but typically less severe than in hEDS.

Submit Your Paper

Vascular EDS (vEDS) is the most serious subtype, characterized by fragile blood vessels and organs that can rupture spontaneously. Patients may have translucent skin revealing underlying blood vessels, distinctive facial features, and are at risk for arterial dissection, organ rupture, and pregnancy complications.

Other subtypes include kyphoscoliotic EDS (severe muscle weakness and spinal curvature), arthrochalasia EDS (extreme joint hypermobility with congenital hip dislocation), and dermatosparaxis EDS (extremely fragile, saggy skin).

Common symptoms across subtypes include chronic fatigue, gastrointestinal problems such as gastroparesis and functional bowel disorders, orthostatic intolerance, and dental issues including crowded teeth and gum disease.

Causes and risk factors

EDS is caused by genetic mutations affecting collagen production, structure, or processing. Different subtypes result from mutations in various genes encoding collagen proteins or enzymes involved in collagen synthesis and modification.

The inheritance patterns vary by subtype. Most forms follow autosomal dominant inheritance, meaning only one copy of the mutated gene is needed to cause the condition. Some subtypes, including kyphoscoliotic EDS and dermatosparaxis EDS, follow autosomal recessive inheritance, requiring two copies of the mutated gene.

Specific genetic causes include mutations in COL5A1 and COL5A2 genes (classical EDS), COL3A1 gene (vascular EDS), PLOD1 and FKBP14 genes (kyphoscoliotic EDS), and ADAMTS2 gene (dermatosparaxis EDS). Hypermobile EDS remains the only subtype without an identified genetic cause, though research suggests it likely involves multiple genetic factors.

The primary risk factor is having an affected parent, as most cases are inherited. However, de novo mutations can occur, meaning EDS can affect individuals with no family history of the condition.

Prevention

As EDS is a genetic condition, primary prevention is not possible. However, genetic counseling and testing play crucial roles in family planning and early detection. Individuals with a family history of EDS or suggestive symptoms should consider genetic counseling to understand inheritance risks and testing options.

Preimplantation genetic diagnosis may be available for families with known mutations, particularly for severe subtypes like vascular EDS. Prenatal testing is possible when the specific familial mutation is known.

Secondary prevention focuses on early recognition and management to prevent complications. Regular screening for cardiovascular issues in vascular EDS, monitoring for spinal progression in kyphoscoliotic EDS, and implementing joint protection strategies can help minimize long-term complications.

Complications

Untreated or poorly managed EDS can lead to significant complications. Joint-related complications include chronic pain, early-onset osteoarthritis, permanent joint deformities, and disability from recurrent dislocations.

Vascular complications are most serious in vascular EDS, including arterial dissection, aneurysm formation, and organ rupture, which can be life-threatening. These complications can occur spontaneously or with minimal trauma.

Spinal complications may include cervical instability, scoliosis, and kyphosis, potentially leading to neurological complications. Cardiac issues can include mitral valve prolapse, aortic root dilation, and in severe cases, valve regurgitation requiring surgical intervention.

Gastrointestinal complications include gastroparesis, intestinal dysmotility, and in rare cases, bowel perforation. Pregnancy complications are particularly concerning in vascular EDS, with increased risks of uterine rupture and major bleeding.

Chronic pain and fatigue can significantly impact quality of life, leading to depression, anxiety, and social isolation. Poor wound healing increases infection risk and can result in delayed recovery from injuries or surgeries.

Diagnosis

EDS diagnosis relies primarily on clinical criteria established by the 2017 International EDS Classification. Each subtype has specific diagnostic criteria combining major and minor clinical features.

For hypermobile EDS, diagnosis requires generalized joint hypermobility (assessed using the Beighton Score), plus additional features including soft skin, unexplained striae, pelvic organ prolapse, and family history.

Genetic testing is available for most EDS subtypes except hypermobile EDS. Testing typically involves sequencing specific genes associated with each subtype. For vascular EDS, biochemical testing of cultured skin fibroblasts can assess collagen production.

Imaging studies may include echocardiography to evaluate cardiac involvement, CT or MR angiography to assess vascular complications in suspected vascular EDS, and spinal imaging to evaluate structural abnormalities.

Specialized assessments may include ophthalmologic examination for corneal fragility and lens abnormalities, dental evaluation for oral manifestations, and orthopedic assessment for joint stability and function.

Treatment

EDS treatment is multidisciplinary and primarily supportive, focusing on symptom management and complication prevention. No curative treatments currently exist.

Physical therapy forms the cornerstone of joint management, emphasizing muscle strengthening, proprioceptive training, and joint protection techniques. Occupational therapy helps with adaptive strategies and assistive devices.

Pain management may involve acetaminophen, topical analgesics, and in some cases, carefully monitored tramadol or gabapentin for neuropathic pain. NSAIDs are often avoided due to bleeding risks, particularly in vascular EDS.

Cardiovascular monitoring is essential, especially in vascular EDS, where celiprolol, a beta-blocker, has shown promise in reducing arterial events. Regular cardiac imaging and blood pressure management are crucial.

Orthotic devices including braces, splints, and supportive garments can help stabilize hypermobile joints and reduce injury risk. Some patients benefit from compression garments for orthostatic intolerance.

Surgical interventions require special considerations due to tissue fragility and poor healing. When necessary, procedures should be performed by experienced surgeons using appropriate techniques and suture materials.

Prognosis

Prognosis varies significantly among EDS subtypes. Hypermobile EDS, while causing chronic pain and functional limitations, typically has a normal life expectancy with appropriate management. Quality of life can be substantially improved through comprehensive care and symptom management.

Vascular EDS has the most serious prognosis, with median life expectancy around 48-50 years due to vascular complications. However, with improved recognition, monitoring, and preventive care, outcomes are improving.

Classical EDS generally has a good prognosis with proper wound care and joint protection, though chronic pain and fatigue can impact quality of life. Other subtypes have variable prognoses depending on the severity of skeletal, ocular, or other systemic involvement.

Early diagnosis and comprehensive management significantly improve outcomes across all subtypes. Patients who receive appropriate care, including physical therapy, pain management, and regular monitoring, often experience better functional outcomes and quality of life.

Quality of life

Living with EDS requires ongoing adaptation and self-management strategies. Regular, low-impact exercise such as swimming, yoga, or tai chi can help maintain joint stability and reduce pain while avoiding high-impact activities that may cause injury.

Dietary considerations may include adequate protein intake to support collagen synthesis, vitamin C supplementation, and managing gastrointestinal symptoms through dietary modifications. Some patients benefit from smaller, more frequent meals to address gastroparesis.

Sleep quality is often compromised by chronic pain and may require specialized mattresses, positioning aids, and sleep hygiene measures. Pain management strategies should address sleep disruption.

Mental health support is crucial, as chronic pain and physical limitations can lead to depression and anxiety. Counseling, support groups, and stress management techniques are valuable components of comprehensive care.

Workplace and school accommodations may include ergonomic modifications, flexible scheduling, and activity limitations. Many patients successfully maintain employment and education with appropriate accommodations.

Pregnancy and fertility

Fertility is generally not affected by most EDS subtypes, though pregnancy requires specialized management. Vascular EDS carries significant pregnancy risks, including increased maternal mortality from uterine rupture and major bleeding complications.

For women with vascular EDS, pregnancy requires high-risk obstetric care with multidisciplinary monitoring. Some experts recommend against pregnancy due to the significant risks, while others support informed decision-making with comprehensive counseling.

Other EDS subtypes may experience increased joint pain, pelvic instability, and wound healing issues during pregnancy. Delivery planning should consider tissue fragility and may favor cesarean section in some cases.

Genetic counseling is recommended for all EDS patients considering pregnancy to discuss inheritance risks and available testing options. Preconception counseling can help optimize health and medication management.

Children

EDS symptoms often begin in childhood but may be dismissed as “growing pains” or attributed to being “double-jointed.” Early recognition is important for implementing protective strategies and preventing injuries.

Pediatric management focuses on safe physical activities, joint protection education, and school accommodations. Contact sports and high-impact activities should generally be avoided.

Educational support may be needed for children with chronic pain, fatigue, or frequent medical appointments. Adaptive physical education and ergonomic considerations can help maintain participation in school activities.

Family education is crucial for recognizing signs of complications and implementing safety measures. Parents should be aware of signs requiring medical attention, particularly in children with vascular EDS.

When to see a doctor

Urgent medical attention is needed for sudden severe chest or abdominal pain, signs of arterial dissection (sudden tearing pain), unusual neurological symptoms, or signs of organ rupture, particularly in patients with vascular EDS.

Routine care should be sought for new joint dislocations, worsening pain patterns, skin changes, cardiovascular symptoms such as palpitations or shortness of breath, and gastrointestinal symptoms.

Individuals should consult a healthcare provider if they experience unusual joint flexibility, skin hyperextensibility, easy bruising, or family history suggestive of EDS. Early evaluation can lead to proper diagnosis and management.

Regular follow-up appointments are essential for monitoring complications, adjusting treatments, and addressing new symptoms as they develop.

Regional context

Limited specific data exists regarding EDS prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. The condition likely occurs at similar rates to global populations, but diagnostic awareness and healthcare access may vary.

Regional genetic founder effects could potentially influence the prevalence of specific EDS subtypes in these populations. Collaborative research efforts would help establish regional epidemiology and identify any population-specific genetic variants.

The Global Medical Journal welcomes contributions from healthcare providers and researchers in these regions to better understand EDS prevalence, presentation patterns, and healthcare challenges specific to Caucasus and Eastern Mediterranean populations.

Research and clinical trials

Current EDS research focuses on identifying the genetic basis of hypermobile EDS, developing targeted therapies, and improving diagnostic methods. Gene therapy approaches are being investigated for various subtypes.

Recent breakthroughs include better understanding of the molecular mechanisms underlying different EDS subtypes and identification of potential therapeutic targets. Research on collagen stabilization and connective tissue strengthening shows promise.

Clinical trials are investigating treatments for pain management, joint stability, and cardiovascular complications. Celiprolol continues to be studied for vascular EDS prevention.

Patients can find current clinical trials through ClinicalTrials.gov using search terms “Ehlers-Danlos syndrome” or specific subtypes. The Ehlers-Danlos Society maintains updated information about research opportunities and studies recruiting participants.

Frequently asked questions

Is EDS progressive?

EDS itself doesn’t typically worsen over time, but complications such as joint damage from repeated dislocations can accumulate. With proper management, many symptoms can be controlled and complications prevented.

Can people with EDS exercise safely?

Yes, but exercise selection is important. Low-impact activities like swimming, yoga, and strengthening exercises are generally recommended, while contact sports and high-impact activities should be avoided.

Is EDS always inherited from parents?

Most cases are inherited, but de novo (new) mutations can occur, meaning some people have EDS without affected parents. Genetic counseling can help clarify inheritance patterns in specific families.

Can EDS be cured?

Currently, no cure exists for EDS. Treatment focuses on managing symptoms, preventing complications, and maintaining quality of life through comprehensive supportive care.

Do all people with joint hypermobility have EDS?

No, joint hypermobility alone is common in the general population. EDS diagnosis requires multiple criteria including specific patterns of hypermobility, skin involvement, and other systemic features.

Support and resources

The Ehlers-Danlos Society (ehlers-danlos.com) – Primary international patient organization providing education, support, and research advocacy.

Orphanet (orpha.net) – Comprehensive rare disease database with detailed EDS information and resources.

National Organization for Rare Disorders (NORD) (rarediseases.org) – Patient advocacy and support organization with EDS resources.

European Rare Diseases Organisation (EURORDIS) (eurordis.org) – European patient advocacy network with EDS support groups.

Genetic and Rare Diseases Information Center (GARD) (rarediseases.info.nih.gov) – NIH resource for rare disease information and support.

Related conditions

Marfan syndrome
Osteogenesis imperfecta
Loeys-Dietz syndrome
Joint hypermobility syndrome
Cutis laxa

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.